In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
News|Articles|December 10, 2015
How the Type of Antiplatelet Agents Can Impact Patient Outcomes
Christopher Betz, PharmD, BCPS, FKSHP, FASHP, professor in the department of clinical and administrative sciences at Sullivan University College of Pharmacy, discusses how the type of antiplatelet agent chosen can impact patient outcomes.
Advertisement
Christopher Betz, PharmD, BCPS, FKSHP, FASHP, professor in the department of clinical and administrative sciences at Sullivan University College of Pharmacy, discusses how the type of antiplatelet agent chosen can impact patient outcomes.
This video was recorded at the 2015 American Society of Health-System Pharmacists Midyear Meeting.
Advertisement
Related to this article
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
Expert Q&A: Geisinger Investigator Discusses Low Flu Vaccination Rates, ICU Findings in Older Adults
A study author explains how pharmacists can help close vaccination gaps in rural communities and what lower ICU admission rates among vaccinated older adults may mean.
From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
Kidney Week 2026 posters show low-density lipoprotein cholesterol (LDL-C) fell by half in patients receiving dialysis, and oral enlicitide needed no dose adjustment for renal impairment.
Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association discusses pharmacists’ role in diabetes and CKD care from ASN Kidney Week 2026
Real-world data from ASN Kidney Week show GLP-1 RA users with CKD and obesity had lower rates of kidney failure, death, and heart failure exacerbation.
Advertisement
Advertisement
Trending on Pharmacy Times
1
COVID-19 ‘Is Not Done With Us’: Pharmacist Urges Continued Vaccination Ahead of Seasonal Peaks
2
Cystatin C and the Future of Kidney Function Assessment
3
Tarlatamab and Next-Generation Targeted Agents Headline ESMO 2026 Lung Cancer Data
4
October 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
5